| Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. G Gasparini, N Weidner, P Bevilacqua, S Maluta, P Dalla Palma, O Caffo, ... Journal of clinical oncology 12 (3), 454-466, 1994 | 607 | 1994 |
| Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy … P Maione, F Perrone, C Gallo, L Manzione, FV Piantedosi, S Barbera, ... Journal of Clinical Oncology 23, 6865-6872, 2005 | 566 | 2005 |
| Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial—FIRSTANA S Oudard, K Fizazi, L Sengeløv, G Daugaard, F Saad, S Hansen, ... Journal of Clinical Oncology 35 (28), 3189-3197, 2017 | 377 | 2017 |
| High syndecan‐1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis M Barbareschi, P Maisonneuve, D Aldovini, MG Cangi, L Pecciarini, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 286 | 2003 |
| Pain and quality of life after surgery for breast cancer O Caffo, M Amichetti, A Ferro, A Lucenti, F Valduga, E Galligioni Breast cancer research and treatment 80, 39-48, 2003 | 271 | 2003 |
| Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. G Gasparini, M Barbareschi, C Doglioni, PD Palma, FA Mauri, P Boracchi, ... Clinical cancer research: an official journal of the American Association …, 1995 | 252 | 1995 |
| A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study C Gridelli, C Gallo, M Di Maio, E Barletta, A Illiano, P Maione, S Salvagni, ... British Journal of Cancer 91 (12), 1996-2004, 2004 | 204 | 2004 |
| Prognostic value of p21 (WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. O Caffo, C Doglioni, S Veronese, M Bonzanini, A Marchetti, F Buttitta, ... Clinical cancer research: an official journal of the American Association …, 1996 | 202 | 1996 |
| Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. G Gasparini, O Caffo, S Barni, L Frontini, A Testolin, RB Guglielmi, ... Journal of clinical oncology 12 (10), 2094-2101, 1994 | 193 | 1994 |
| Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up M Barbareschi, O Caffo, S Veronese, RD Leek, P Fina, S Fox, ... Human pathology 27 (11), 1149-1155, 1996 | 167 | 1996 |
| Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone C Lolli, O Caffo, E Scarpi, M Aieta, V Conteduca, F Maines, E Bianchi, ... Frontiers in pharmacology 7, 376, 2016 | 159 | 2016 |
| Activity of pemetrexed on brain metastases from non-small cell lung cancer A Bearz, I Garassino, M Tiseo, O Caffo, H Soto-Parra, M Boccalon, ... Lung Cancer 68 (2), 264-268, 2010 | 145 | 2010 |
| p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein … M Barbareschi, O Caffo, C Doglioni, P Fina, A Marchetti, F Buttitta, R Leek, ... British journal of cancer 74 (2), 208-215, 1996 | 143 | 1996 |
| Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma: A survey by a self‐administered questionnaire O Caffo, G Fellin, U Graffer, L Luciani Cancer: Interdisciplinary International Journal of the American Cancer …, 1996 | 140 | 1996 |
| Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ... Journal of Clinical Oncology 41 (18), 3339-3351, 2023 | 131 | 2023 |
| Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma—results of a multiparametric study P Bevilacqua, M Barbareschi, P Verderio, P Boracchi, O Caffo, PD Palma, ... Breast cancer research and treatment 36, 205-217, 1995 | 129 | 1995 |
| c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma—an immunocytochemical study G Gasparini, F Pozza, P Bevilacqua, WJ Gullick, NR Lemoine, S Maluta, ... European Journal of Cancer 30 (1), 16-22, 1994 | 115 | 1994 |
| Microvessel density quantification in breast carcinomas. Assessment by light microscopy vs. a computer-aided image analysis system M Barbareschi, N Weidner, G Gasparini, L Morelli, S Forti, C Eccher, ... Appl Immunohistochem 3 (75), 1995-84, 1995 | 108 | 1995 |
| Cyclin‐d1‐gene amplification and expression in breast carcinoma: Relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21waf1 … M Barbareschi, P Pelosio, O Caffo, F Buttitta, S Pellegrini, R Barbazza, ... International journal of cancer 74 (2), 171-174, 1997 | 99 | 1997 |
| Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment … O Caffo, U De Giorgi, L Fratino, D Alesini, V Zagonel, G Facchini, ... European urology 68 (1), 147-153, 2015 | 98 | 2015 |
